Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
Reads0
Chats0
TLDR
Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.Abstract:
Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent monomethylauristatin E to CD30-positive malignant cells. A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL. Patients and Methods Patients with systemic ALCL and recurrent disease after at least one prior therapy received brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks over 30 minutes as an outpatient infusion. The primary end point of the study was overall objective response rate as assessed by independent central review. Results Of 58 patients treated in the study, 50 patients (86%) achieved an objective response, 33 patients (57%) achieved a complete remission (CR), and 17 patients (29%) achieved a partial remission. The median durations of overall respons...read more
Citations
More filters
Journal ArticleDOI
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers,Peter D. Senter +1 more
TL;DR: Key characteristics of current, clinically active antibody-drug conjugate patients are summarized and recent clinical data illustrating the benefit of antibody-targeted delivery of cytotoxic agents to cancer cells are highlighted.
Journal ArticleDOI
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter,Eric L. Sievers +1 more
TL;DR: Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies.
Journal ArticleDOI
Declining childhood and adolescent cancer mortality.
TL;DR: To evaluate whether progress continues in identifying more effective treatments for children and adolescents with cancer, the authors examined both overall and disease‐specific childhood cancer mortality rates for the United States, focusing on data from 2000 to 2010.
Journal ArticleDOI
Antibody-Drug Conjugates: A Comprehensive Review
TL;DR: This review provides an overview of the systemic evaluation of each component of an ADC design, improved understanding of the mechanism of action of ADC, and mechanistic pathways involved in ADC resistance and various strategies to optimize ADC design.
Journal ArticleDOI
Antibody-drug conjugates for cancer therapy.
TL;DR: Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy, and further improvements in antibody- drug linker technology.
References
More filters
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
The Robust Inference for the Cox Proportional Hazards Model
Danyu Lin,L. J. Wei +1 more
TL;DR: In this article, the authors derived the asymptotic distribution of the maximum partial likelihood estimator β for the vector of regression coefficients β under a possibly misspecified Cox proportional hazards model.
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes,Nancy L. Bartlett,John P. Leonard,Dana A. Kennedy,Carmel M. Lynch,Eric L. Sievers,Andres Forero-Torres +6 more
TL;DR: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.
Journal ArticleDOI
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier,Catherine Thieblemont,Eric Van Den Neste,Gérard Lepeu,Isabelle Plantier,Sylvie Castaigne,Sophie Lefort,Gerald Marit,Margaret Macro,Catherine Sebban,Karim Belhadj,Dominique Bordessoule,Christophe Fermé,Hervé Tilly +13 more
TL;DR: The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP and underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.
Related Papers (5)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier,Barbara Pro,H. Miles Prince,Francine M. Foss,Lubomir Sokol,Matthew Greenwood,Dolores Caballero,Peter Borchmann,Franck Morschhauser,Martin Wilhelm,Lauren Pinter-Brown,Swaminathan Padmanabhan,Andrei R. Shustov,Jean Nichols,Susan Carroll,John Balser,Barbara Balser,Steven M. Horwitz +17 more